S1204, Viral Screening in Newly Diagnosed Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.

Detailed Description
-----------------
Primary Objective Among newly diagnosed cancer patients presenting to SWOG-affiliated community and academic oncology clinics, estimate the prevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection. Prevalence estimates will be further stratified: by whether infection with the virus(es) is known, as reported by patients and/or their physician prior to study testing, vs. unknown; by presenting cancer type, and by self-reported risk factors for each virus. Secondary Objectives Evaluate known sociodemographic, clinical, and behavioral factors that are significantly associated with previously undiagnosed HIV, HBV, and/or HCV infection in a population of people with newly diagnosed cancer. Among patients who are identified as having HIV, HBV, and/or HCV, evaluate the timing and type of treatments received, both for the viral infections and the cancers. Evaluate type and rate of cancer treatment-related adverse events in patients with HIV, HBV, and/or HCV infection. Using simulation modeling that is directly informed by the data obtained from this study, determine the cost-effectiveness (expressed as cost per infection detected and cost per year of life gained) of (1) routine, universal screening and (2) risk factor-directed screening of newly diagnosed cancer patients for HIV, HBV, and/or HCV vs. current care. Tertiary Objective Create a biorepository of stored serum for future translational medicine studies that may include identifying genomic and viral factors that increase the risk of serious adverse effects among participants infected with HIV, HBV, and/or HCV being treated for invasive cancers.

Official Title
-----------------
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presenting for evaluation or treatment of a new cancer malignancy(including hematologic) confirmed pathologic diagnosis must be within 120 days of registration (Patients presenting for second opinions of confirmed malignancies are eligible, including those who have started cancer treatment at other facilities) at least 18 years of age patient must have had their blood drawn for HIV, HBV and HCV testing prior to registration (Patients who have had HIV, HBV and/or HCV testing within 60 days prior to registration and who do not wish to be retested are eligible, provided supporting documents can be obtained confirming viral test results for all three viruses. Documentation must be obtained prior to registration. Patients who are viral positive for either HIV, HBV, and/or HCV and who do not wish to be retested are eligible, provided documentation of viral load within 120 days prior to registration can be obtained. Note that these patients must be tested for or provide current viral load for all three viruses to be eligible. Documentation must be obtained prior to registration.) Patients must sign and give written informed consent in accordance with institutional and federal guidelines Patients must be offered the opportunity to allow their blood specimens to be banked by the SWOG Repository for future research Exclusion Criteria: diagnosed with a malignancy other than the current malignancy within the past five years (with the exception of basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ breast cancer.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Positive Viral Infection | An estimate of the prevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection among newly diagnosed cancer participants presenting to SWOG-affiliated community and academic oncology clinics. | Up to 21 days after registration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of Important Risk Factors in Participants Tested for Previous HBV | The presence or absence of specific risk factors among participants evaluated for previous HBV is evaluated. | Up to 21 days after registration | 
| Presence of Important Risk Factors in Participants Tested for Chronic HBV | The presence or absence of specific risk factors among participants evaluated for chronic HBV is evaluated. | Up to 21 days after registration | 
| Presence of Important Risk Factors in Participants Tested for HCV | The presence or absence of specific risk factors among participants evaluated for HCV is evaluated. | Up to 21 days after registration | 
| Presence of Important Risk Factors in Participants Tested for HIV | The presence or absence of specific risk factors among participants evaluated for HIV is evaluated. | Up to 21 days after registration | 
| Type of Treatment for Cancer and Virus in Participants With Positive Viral Test | Among participants with HIV, HBV, or HCV, the timing and type of treatments received, both for the viral infections and the cancers that were evaluated. | 60 days after registration | 
| Type and Rate of Adverse Events Among Patients With Viral Infection. | Estimate type and rate of cancer-treatment related adverse events among persons with HIV, HBV, and/or HCV infection. | 5 years after registration | 
| Cost-effectiveness of Viral Screening | Estimate the cost-effectiveness of screening for HIV, HBV, and HCV. | 3 years after registration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
viral screening